Rukobia (fostemsavir) Disease Interactions
There are 2 disease interactions with Rukobia (fostemsavir):
Fostemsavir (Includes Rukobia) ↔ hepatitis B
Moderate Potential Hazard, Moderate plausibility. Applies to: Infectious Hepatitis
Fostemsavir may cause elevations in hepatic transaminases in patients co-infected with hepatitis B or C. It is recommended to monitor liver function in patients with hepatitis B or C co-infection. Particular attention should be practiced in initiating or maintaining effective hepatitis B therapy when starting fostemsavir treatment in patients co-infected with hepatitis B.
Fostemsavir (Includes Rukobia) ↔ QT prolongation
Moderate Potential Hazard, Moderate plausibility. Applies to: Heart Disease
Fostemsavir has been shown to significantly prolong the QTc interval of the electrocardiogram with higher than recommended dosages. Fostemsavir should be used with caution in patients with a history of QTc interval prolongation, when co-administered with a drug with a known risk of Torsade de Pointes, or in patients with relevant preexisting cardiac disease.
Rukobia (fostemsavir) drug interactions
There are 338 drug interactions with Rukobia (fostemsavir)
More about Rukobia (fostemsavir)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: miscellaneous antivirals
- FDA Approval History
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.